Provider of respiratory monitoring technology PMD Solutions has been selected to join the NHS Innovation Accelerator Programme.
Stethoscope
The NHS Innovation Programme is a partnership between England’s 15 Academic Health Science Networks (AHSNs) and is focused on working with healthcare innovators.
The announcement from the world’s largest healthcare conference Medica, where PMD Solutions was showcasing its RespiraSense product, a device which can continuously monitor patients’ respiratory rates. The device can help detect patient deterioration up to 12 hours in advance of an adverse patient event, allowing healthcare professionals to intervene faster.
PMD Solutions was invited by Enterprise Ireland to be part of the Irish pavilion where they represented alongside some of the world’s leading medtec organisations.
The NHS will rapidly adopt the company’s RespiraSense product to help improve the standard of care throughout the UK. The device is currently being piloted in Portsmouth, Bradford and London hospitals as part of the Innovation Programme.
RespiraSense is currently awaiting FDA clearance but PMD Solutions expect it to be available for sale within the US sometime next year.
Minister for Trade, Employment, and Business, Pat Breen TD said: "I am delighted but not surprised with PMD Solutions' recent successes. I had the pleasure of visiting them at this year's Medica event and was extremely impressed by their high levels of innovation and entrepreneurship. It is wonderful to see an Irish company at the forefront of medical technology advances. They serve as a great example to all Irish companies with ambitions to trade internationally."
Sheila O'Loughlin, senior market adviser, Enterprise Ireland said: "PMD Solutions has achieved significant traction in the UK market, further strengthened by its recent acceptance on the prestigious NHS Innovation Accelerator Programme. We will continue to support them as they expand in to European and global markets."
Speaking about the company's recent successes, Myles Murray, CEO, PMD Solutions said: "We are most grateful to Enterprise Ireland for giving us this fantastic opportunity to showcase RespiraSense to the global healthcare industry. We have created an innovation that is set to change the face of in hospital monitoring at a global scale, improve patient outcomes and generate substantial cost savings for healthcare providers."
Murray continued: "We are a young company with big ambition. The recent NHS announcement, coupled with Medica has allowed us to engage with global leaders and positioned PMD as an international clinical differentiator in the patient monitoring market."
